false 0001323885 0001323885 2021-05-20 2021-05-20

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

of the SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 20, 2021

 

 

AtriCure, Inc.

(Exact name of registrant as specified in charter)

 

 

 

Delaware   000-51470   34-1940305

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

7555 Innovation Way, Mason OH 45040

(Address of Principal Executive Offices, and Zip Code)

(513) 755-4100

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $.001 par value   ATRC   NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.07

Submission of Matter to a Vote of Security Holders

The stockholders of AtriCure, Inc. (the “Company”) voted on the following items at the Annual Meeting of Stockholders held on May 20, 2021:

 

  1.

The election of eight directors to serve one-year terms expiring at the 2022 Annual Meeting of Stockholders and until their successors have been duly elected and qualified;

 

  2.

A proposal to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021; and

 

  3.

An advisory vote on the compensation of the Company’s named executive officers as disclosed in the proxy statement.

The nominees for director were elected based upon the following votes:

 

Director Nominees

  

For

  

Against

  

Abstain

  

Broker Non-Votes

Michael H. Carrel

   40,013,214    1,143,119    15,350    2,348,347

Mark A. Collar

   33,268,636    7,887,582    15,465    2,348,347

Daniel P. Florin

   41,102,530    53,803    15,350    2,348,347

Regina E. Groves

   41,103,119    53,564    15,000    2,348,347

B. Kristine Johnson

   39,753,703    1,402,979    15,001    2,348,347

Karen N. Prange

   37,567,891    3,588,792    15,000    2,348,347

Sven A. Wehrwein

   41,102,315    54,018    15,350    2,348,347

Robert S. White

   37,610,362    3,545,971    15,350    2,348,347

The proposal to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 received the following votes:

 

For:

     43,220,007  

Against:

     290,720  

Abstain:

     9,303  

Broker Non-Votes:

     0  

The advisory vote on the compensation of the Company’s named executive officers as disclosed in the proxy statement received the following votes:

 

For:

     39,361,546  

Against:

     1,793,104  

Abstain:

     17,033  

Broker Non-Votes:

     2,348,347  


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ATRICURE, INC.
Dated: May 24, 2021     By:  

/s/ Angela L. Wirick

      Angela L. Wirick
      Chief Financial Officer
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more AtriCure Charts.
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more AtriCure Charts.